Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.

Kim RJ, Rutstein RM.

Paediatr Drugs. 2010 Jun;12(3):187-99. doi: 10.2165/11532520-000000000-00000. Review.

PMID:
20481647
2.

The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).

Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B.

Horm Metab Res. 2009 Jul;41(7):573-9. doi: 10.1055/s-0029-1202779. Epub 2009 Mar 25.

PMID:
19322744
3.

Metabolic complications of antiretroviral therapy in children.

Leonard EG, McComsey GA.

Pediatr Infect Dis J. 2003 Jan;22(1):77-84. Review.

PMID:
12544413
4.

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.

Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP.

AIDS. 2008 Jan 11;22(2):227-36.

PMID:
18097225
5.

Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy.

Morén C, Noguera-Julian A, Rovira N, Corrales E, Garrabou G, Hernández S, Nicolás M, Tobías E, Cardellach F, Miró O, Fortuny C.

Pediatr Infect Dis J. 2011 Nov;30(11):992-5. doi: 10.1097/INF.0b013e3182253c54.

PMID:
21697766
7.
8.
9.

Endothelial markers and HIV infection in the era of highly active antiretroviral treatment.

de Larrañaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA.

Thromb Res. 2003 May 1;110(2-3):93-8.

PMID:
12893023
10.

HIV infection--a risk factor for osteoporosis.

Thomas J, Doherty SM.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):281-91. Review.

PMID:
12843738
11.

Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment.

Schwenk A, Beisenherz A, Kremer G, Diehl V, Salzberger B, Fätkenheuer G.

Am J Clin Nutr. 1999 Nov;70(5):867-73.

12.

Lipodystrophy syndrome in human immunodeficiency virus-infected children.

Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW.

Pediatr Infect Dis J. 2002 May;21(5):405-10.

PMID:
12150177
13.

Abnormalities in body composition and nutritional status in HIV-infected children and adolescents on antiretroviral therapy.

Ramalho LC, Gonçalves EM, de Carvalho WR, Guerra-Junior G, Centeville M, Aoki FH, Morcillo AM, dos Santos Vilela MM, da Silva MT.

Int J STD AIDS. 2011 Aug;22(8):453-6. doi: 10.1258/ijsa.2011.010516.

PMID:
21795418
14.

Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.

Gougeon ML, Pénicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J.

Antivir Ther. 2004 Apr;9(2):161-77. Review.

PMID:
15134178
15.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
16.

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.

Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R, Zeichner S.

Pediatrics. 2004 Aug;114(2):e235-42.

PMID:
15286262
17.
18.

[Effect of anti-retroviral therapy on body composition changes: a literature review].

Dell'Isola C, Aprea L, Pizzella T, Izzo C.

Infez Med. 2006 Mar;14(1):5-12. Review. Italian.

19.

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.

Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):482-9.

PMID:
12679698
20.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503

Supplemental Content

Support Center